Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
ARA-290 (Cibinetide) ARA-290 is generally well-tolerated in clinical and preclinical research, with no evidence of erythropoietic activity or thrombotic risk associated with full-length EPO
In particular, inhibitors or activators targeting cellular components, as well as biomolecules, enzymes, and nutrients, can stimulate apoptotic signaling pathways
More broadly, it is possible that rapid growth per se compensates for damage to an enzyme population, by rapidly replacing them through ongoing synthesis
Historical IV protocols used 500-1,000 mg per session
US$ 20.31
US$ 20.63
US$ 27.20
